{"id":1115057,"date":"2023-05-31T19:48:41","date_gmt":"2023-05-31T23:48:41","guid":{"rendered":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/uncategorized\/tremfya-potential-highlighted-by-industry-analyst-globaldata-the-pharma-letter\/"},"modified":"2023-05-31T19:48:41","modified_gmt":"2023-05-31T23:48:41","slug":"tremfya-potential-highlighted-by-industry-analyst-globaldata-the-pharma-letter","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/tremfya-potential-highlighted-by-industry-analyst-globaldata-the-pharma-letter\/","title":{"rendered":"Tremfya potential highlighted by industry analyst GlobalData &#8211; The Pharma Letter"},"content":{"rendered":"<p><p>    Industry analyst GlobalData has highlighted    research showing the potential of Janssens Tremfya    (guselkumab) in the treatment of psoriasis.  <\/p>\n<p>    Johnson & Johnsons (NYSE: JNJ) biotech    subsidiary has recently released new data on the interleukin    (IL)-23-targeting antibody in adults with moderate-to-severe    plaque psoriasis (PsO).  <\/p>\n<p>    A real-world data analysis and the results of    J&Js Phase III VOYAGE 2 study suggest the product    could  <\/p>\n<p>    This article is accessible to registered users, to continue    reading please register    for free. A free trial will give you access to    exclusive features, interviews, round-ups and commentary from    the sharpest minds in the pharmaceutical and biotechnology    space for a week. If you are already a registered user    pleaselogin. If your trial has    come to an end, you cansubscribe here.  <\/p>\n<\/p>\n<p>    Try before you buy  <\/p>\n<p>     All the news that moves the needle in pharma and biotech.     Exclusive features, podcasts, interviews, data analyses and    commentary from our global network of life sciences    reporters.     Receive The Pharma Letter daily news bulletin, free    forever.  <\/p>\n<p>    Become a subscriber  <\/p>\n<p>     Unfettered access to industry-leading news, commentary and    analysis in pharma and biotech.     Updates from clinical trials, conferences, M&A,    licensing, financing, regulation, patents & legal, executive    appointments, commercial strategy and financial results.     Daily roundup of key events in pharma and biotech.     Monthly in-depth briefings on Boardroom appointments and    M&A news.     Choose from a cost-effective annual package or a flexible    monthly subscription.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more here:<br \/>\n<a target=\"_blank\" href=\"https:\/\/www.thepharmaletter.com\/article\/tremfya-potential-highlighted-by-industry-analyst-globaldata\" title=\"Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter\" rel=\"noopener\">Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Industry analyst GlobalData has highlighted research showing the potential of Janssens Tremfya (guselkumab) in the treatment of psoriasis. Johnson &#038; Johnsons (NYSE: JNJ) biotech subsidiary has recently released new data on the interleukin (IL)-23-targeting antibody in adults with moderate-to-severe plaque psoriasis (PsO).  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/tremfya-potential-highlighted-by-industry-analyst-globaldata-the-pharma-letter\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1115057","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1115057"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=1115057"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1115057\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=1115057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=1115057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=1115057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}